Rubric Capital Management LP Has $288.42 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Rubric Capital Management LP lessened its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.3% during the third quarter, Holdings Channel.com reports. The fund owned 16,005,498 shares of the company’s stock after selling 1,256,243 shares during the period. Teva Pharmaceutical Industries accounts for 4.7% of Rubric Capital Management LP’s holdings, making the stock its 2nd largest holding. Rubric Capital Management LP’s holdings in Teva Pharmaceutical Industries were worth $288,419,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. New Covenant Trust Company N.A. bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth about $28,000. EntryPoint Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth approximately $30,000. UMB Bank n.a. grew its position in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at approximately $48,000. Finally, Smithfield Trust Co lifted its stake in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on TEVA shares. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, October 21st. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Down 0.6 %

Shares of TEVA opened at $16.59 on Wednesday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The business’s 50 day moving average price is $17.62 and its 200-day moving average price is $17.36. Teva Pharmaceutical Industries Limited has a 52 week low of $9.35 and a 52 week high of $19.31.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.